Departments of Neurology (G.P., A.P., S.D., D.S.L., J.D.H.), David Geffen School of Medicine, University of California, Los Angeles.
Radiology (N.K.), David Geffen School of Medicine, University of California, Los Angeles.
Stroke. 2024 Jun;55(6):1707-1719. doi: 10.1161/STROKEAHA.124.044520. Epub 2024 May 13.
Intracranial atherosclerotic disease (ICAD) is a leading cause of ischemic stroke worldwide. However, research on the pathophysiology of ICAD is scarce due to the relative inaccessibility of histology samples and the lack of comprehensive experimental models. As a result, much of the current understanding of ICAD relies on research on extracranial atherosclerosis. This approach is problematic as intracranial and extracranial arteries are anatomically, structurally, physiologically, and metabolically distinct, indicating that intracranial and extracranial atherosclerosis likely develop through different biologic pathways. The current standard of care for ICAD treatment relies predominantly on therapeutics developed to treat extracranial atherosclerosis and is insufficient given the alarmingly high risk of stroke. To provide a definitive treatment for the disease, a deeper understanding of the pathophysiology underlying ICAD is specifically required. True mechanistic understanding of disease pathogenesis is only possible using robust experimental models. In this review, we aim to identify the advantages and limitations of the existing in vivo and in vitro models of ICAD and basic atherosclerotic processes, which may be used to inform better models of ICAD in the future and drive new therapeutic strategies to reduce stroke risk.
颅内动脉粥样硬化性疾病 (ICAD) 是全球缺血性卒中的主要病因。然而,由于组织学样本相对难以获得以及缺乏全面的实验模型,ICAD 的病理生理学研究仍然很少。因此,目前对 ICAD 的大部分了解都依赖于对外周动脉粥样硬化的研究。这种方法存在问题,因为颅内动脉和颅外动脉在解剖学、结构、生理学和代谢方面存在明显差异,这表明颅内和颅外动脉粥样硬化可能通过不同的生物学途径发展。目前 ICAD 治疗的标准疗法主要依赖于为治疗颅外动脉粥样硬化而开发的疗法,但鉴于卒中风险高得惊人,这种疗法远远不够。为了为该疾病提供明确的治疗方法,特别需要深入了解 ICAD 的病理生理学基础。只有使用强大的实验模型才能真正实现对疾病发病机制的机制理解。在这篇综述中,我们旨在确定现有的 ICAD 及基础动脉粥样硬化过程的体内和体外模型的优缺点和局限性,这些模型可能有助于未来开发出更好的 ICAD 模型,并推动新的治疗策略来降低卒中风险。